Satellite symposia are non-commercial, grant- funded learning activities that are planned and conducted by the corporate community in conjunction with AMCP 2025. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.
Registration, content, and continuing education are the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.
Satellite program information will be available in late January.
For more information, please contact us.
- Monday, March 31, 2025 | 6:00 pm - 8:00 pm
-
Location: 330
Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens
Provider: Pharmacy Times Continuing Education
Supported by: GSK and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Continuing education: Managed Care Pharmacist, Oncology pharmacist
Contact hours: 1.5
Program Description
There have been significant advancements in the management of multiple myeloma (MM), leading to improved survival rates. However, relapse remains an inevitable part of the disease course. Novel treatment approaches, including bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs) have emerged as effective treatment modalities for relapsed or refractory disease, though these therapies are associated with significant toxicities and operational barriers that complicate their use. Managed care pharmacists play a crucial role in developing utilization protocols aimed to reduce operational barriers, resolve administration challenges, and optimize resource utilization. This session will examine the most recent clinical evidence and guideline recommendations for the use of BsAbs and ADCs in the treatment of relapsed/refractory MM to prepare managed care professionals to design workflows that reduce barriers to access to these treatments and ensure appropriate resource allocation.
Learning Objectives
- Differentiate the mechanisms and nuances between antibody-drug conjugates (ADCs) and bispecific antibody (BsAb) therapies that drive treatment decisions for the use in multiple myeloma (MM).
- Dissect the recent clinical data of antibody-based regimens in the treatment of MM.
- Compare the guideline-recommended use of BsAbs and ADCs in the treatment of relapsed/refractory MM.
- Investigate operational strategies to optimize access and safety of antibody-based regimens in the treatment of relapsed/refractory MM.
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com
- Monday, March 31, 2025 | 6:00 pm - 8:00 pm
-
Location: 340
PayerTalkCE® Presents: Managed Care Strategies to Improve Outcomes for Macular Telangiectasia
Provider: Impact Education, LLC and Partners in Advancing Clinical Education
Supported by: neurotech
Contact hours: 1.5 CPE/CME/CNE credits
Program DescriptionWith a therapy recently approved for the treatment of MacTel and others in late-stage development, managed care professionals must remain informed regarding available clinical trial data and prepare to incorporate emerging treatments into coverage policies to optimize healthcare resources and improve patient outcomes. Managed care pharmacists and other payer professionals will receive knowledge on the timely diagnosis and appropriate treatment of MacTel, including the current and evolving clinical data, the need for multidisciplinary patient care, and benefit design strategies to ensure access to appropriate and effective MacTel therapy.
Learning Objectives
- Describe the natural history, disease mechanisms, and clinical goals of timely treatment of macular telangiectasia
- Review the safety and efficacy data for current and emerging macular telangiectasia treatment options
- Describe the value of multidisciplinary care approaches for patients with macular telangiectasia to improve patient outcomes and coordination of care
- Identify benefit design strategies that ensure access to appropriate and effective macular telangiectasia therapies
Program Manager
Allison Hartless
Impact Education, LLC
allison.hartless@impactedu.net
- Tuesday, April 1, 2025 | 11:30 am - 1:30 pm
-
Location: 330
Managed Care Considerations for Managing Myelofibrosis With JAK Inhibitors
Provider: Medscape LLC
Supported by: Supported by an independent educational grant from GSK
Continuing education: For Pharmacists
Medscape designates this continuing education activity for 1.50 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-25-007-L01-P).
Contact hours: 1.5Program Description
In this 90-minute symposium, a panel of 3 expert managed care pharmacists will discuss evidence- and value-based strategies for optimal integration of Janus kinase (JAK) inhibitors into the treatment plan for patients with myelofibrosis (MF). The faculty will begin with an overview of the MF disease burden, prognostic risk scoring systems, and current treatment landscape, with a focus on topline clinical trial safety and efficacy data for the 4 JAK inhibitors now approved for use in higher-risk MF and MF-associated anemia. After detailed guidance on the role of pharmacists in dose optimization, mitigation and management of treatment-related adverse events (TRAEs), and patient education and counseling, the discussion will turn to economic and logistical considerations for managed care pharmacists seeking to optimize access to the full range of JAK inhibitors across the treatment continuum. The program will conclude with a roundtable discussion about overcoming barriers to successful integration of JAK inhibitors in managed care settings, closing with an interactive audience Q&A session.
Learning Objectives
Upon completion of this activity, participants will:
- Have increased knowledge regarding the
- Managed care pharmacy considerations that impact use of JAK inhibitors in management of MF
Characteristics of JAK inhibitors that drive decision making
- Have greater competence related to
- Implementing pharmacy benefit design to improve access to JAK inhibitors in management of MF
Demonstrate greater confidence in their ability to
- Optimize use of JAK inhibitors as part the MF treatment pan managed care settings
Program Manager
Nora Pettit
Medscape LLC
npettit@medscapelive.com - Tuesday, April 1, 2025 | 11:30 am - 1:30 pm
-
Location: 340
Managed Care Review Board™ Presents: Health Plan Best Practice Insights to Improve Outcomes for Non-Small Cell Lung Cancer
Provider: Impact Education, LLC and Medical Education Resources, Inc.
Supported by: Regeneron Pharmaceuticals, Inc.
Contact hours: 1.5 CPE/CME/CNE creditsProgram Description
Attendees will learn about current treatment paradigms, emerging treatment options, and current screening and biomarker testing guidelines for NSCLC. This symposium will also address how to evaluate the cost-effectiveness of various NSCLC treatment options to inform decision-making and optimize health care resource allocation, all while touching on the impact of social determinants of health on patients with NSCLC.
Learning Objectives
- Outline current recommendations for screening of NSCLC and characterization of the disease at diagnosis to drive appropriate treatment selection
- Evaluate the cost-effectiveness of various treatment options for NSCLC to inform decision-making and optimize healthcare resource allocation
- Discuss relevant social determinants of health-related to NSCLC treatment
Program Manager
Allison Hartless
Impact Education, LLC
allison.hartless@impactedu.net - Tuesday, April 1, 2025 | 11:30 am - 1:30 pm
-
Location: 370 ABC
Hit the Ground Running in Crohn’s Disease: A Managed Care Guide to Advanced Biologic Therapies and Early Interventions to Improve Long-term Outcomes
Provider: ProCE, LLC
Continuing education: The target audience for this activity is population health decision-makers involved in the care of patients with CD, comprising managed care pharmacists, payers, pharmacy benefit managers, and key managed care pharmacy stakeholders, pharmacy directors, chief pharmacy officers, and other managed care professionals, as well as members of integrated delivery systems, such as specialty pharmacists.
Contact hours: 1.5Program Description
As medical science advances have generated new biologic therapies for the treatment of Crohn’s disease (CD), managed care pharmacists and other healthcare professionals who serve as population health decision-makers must stay abreast of the clinical evidence regarding the utility of new therapies in achieving the guideline-recommended treatment targets that improve long-term disease remission and ultimately help reduce healthcare utilization and costs. Evidence demonstrates that individuals with CD who reach the most stringent treatment goals of deep mucosal healing have lower rates of clinical relapse, hospitalization, surgery, and cancer. Fortunately, new and emerging biologic therapies such as selective interleukin-23 (IL-23) inhibitors are helping patients achieve rapid symptom improvement and durable disease remission. Yet, delays in treatment initiation are common and most patients do not receive early treatment with advanced therapies as recommended by expert consensus. With the significant impact of CD on both patients and the healthcare system, managed care professionals are tasked with leveraging a comprehensive understanding of disease burden andunmet needs, the latest clinical data on current and emerging therapies, and strategies for optimizing patient care.to achieve the best possible clinical outcomes.
Join us for this interactive and engaging ACPE-certified education to reflect and connect with experts on advances in biologic therapies for moderate to severe CD.
Learning Objectives
- Analyze the safety and efficacy data informing the use of selective IL-23 inhibitors in moderate to severe CD
- Assess the contribution of suboptimal therapy to healthcare utilization and costs for patients with moderate to severe CD
- Identify managed care considerations that incorporate evidence-based data on novel biologic therapies into formulary decisions and pathway development to prevent delays in therapy and improve clinical outcomes in the management of moderate to severe CD
Program Manager
Kerry Rosa
ProCE
krosa@cealliance.com - Tuesday, April 1, 2025 | 11:30 am - 1:30 pm
-
Location: 370 DEF
Leveraging Managed Care to Optimize Patient Outcomes - Integrating Novel Treatments in Schizophrenia
Provider: Pharmacy Times Continuing Education
Supported by: Boehringer Ingelheim Pharmaceuticals, Inc.
Continuing education: Managed Care Pharmacist
Contact hours: 1.5
Program Description
Schizophrenia is a complex psychiatric disorder that can significantly impact patients, families, and health care systems. Despite improvements in treatments, many standard therapies still have limitations, with only half of patients able to lead normal lives. Novel therapeutic targets and approaches are needed to address negative symptoms and cognitive dysfunction, and long-acting injectables (LAIs) offer a transformative approach to overcoming barriers such as medication nonadherence. Disparities persist in management, leading to variations in care quality and patient outcomes. Managed care professionals need to integrate new classes of medications to address unmet needs and ensure timely and equitable access while advancing the standard of care for individuals living with schizophrenia. This program will explore the evolving understanding of the symptomatology and disease burden of schizophrenia, while highlighting recent innovations in treatment as well as challenges in management and its economic impact. Managed care professionals and pharmacists will gain actionable insights into the benefits of LAIs in improving adherence, reducing health care resource utilization, and enhancing patient outcomes.
Learning Objectives
- Explore the epidemiology and the unmet needs affecting the lifelong management of patients with schizophrenia.
- Analyze recent clinical data on novel treatment approaches for schizophrenia.
- Apply managed care strategies to optimally integrate novel treatment strategies within the treatment paradigm of schizophrenia care.
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com - Tuesday, April 1, 2025 | 6:00 pm - 8:00 pm
-
Location: 370 ABC
Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage
Provider: Pharmacy Times Continuing Education
Supported by: GSK
Continuing education: Managed Care Pharmacist
Contact hours: 1.5
Program Description
Respiratory syncytial virus (RSV) poses a significant health threat to older adults, contributing to substantial morbidity, hospitalizations, and health care costs annually. Prevention strategies have become a critical focus in clinical practice to reduce morbidity and mortality in older adults. Recently approved vaccines represent new approaches to reduce the burden of RSV-related complications. This program will provide an in-depth look at the pathology, clinical manifestations, and impact on public health of RSV, while highlighting the efficacy, safety, and cost-effectiveness of available vaccines for RSV. Managed care professionals will gain actionable strategies to implement ACIP recommendations, promote equitable access to RSV vaccination, and reduce health care resource utilization.
Learning Objectives
- Examine the economic and clinical burden of respiratory syncytial virus (RSV) lower respiratory tract disease .
- Analyze the latest clinical data for recently approved and emerging vaccines for RSV.
- Identify managed care initiatives to facilitate the uptake of new RSV immunization strategies to reduce the impact of RSV in adults and on the health care system
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com - Tuesday, April 1, 2025 | 6:00 pm - 8:00 pm
-
Location: 370 DEF
Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists
Provider: Pharmacy Times Continuing Education
Supported by: Novo Nordisk
Continuing education: Managed Care Pharmacist
Contact hours: 1.5
Program Description
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease caused by excessive fat accumulation in the liver that induces chronic inflammation. Greater understanding of its pathogenesis and progression has led to the development of THR-β agonists and GLP-1/glucagon receptor agonists targeting obesity and other metabolic syndrome components. This session will review current diagnostic approaches, challenges associated with misdiagnosis and delayed diagnosis of MASH, and relevant guidelines to inform evidence-based care. The economic burden of MASH will also be addressed, highlighting opportunities for specialty and managed care pharmacists to optimize health care resource utilization and prepare them to support treatment access and coverage decisions for recently approved and emerging therapies.
Learning Objectives
- Examine the epidemiology, pathophysiology, clinical presentation and comorbidities, diagnosis, and burden of disease in metabolic dysfunction-associated steatohepatitis (MASH)
- Analyze the efficacy and safety profiles of approved and emerging therapies for treating MASH
- Employ effective managed care strategies for optimizing patient outcomes using managed care insights to enable timely MASH diagnosis and enhanced access to evidence-based treatments
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com - Wednesday, April 2, 2025 | 6:00 am - 8:00 am
-
Location: 370 ABC
Navigating the Advancements in Oral Therapy Options in HR+ Metastatic Breast Cancer
Provider: Pharmacy Times Continuing Education
Supported by: This educational activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Stemline Therapeutics, Inc.
Continuing education: Managed Care Pharmacist, Oncology Pharmacist
Contact hours: 1.5
Program Description
The managed care environment faces new pharmacoeconomic barriers with the increasing complexity of targeted therapies and introduction of novel agents in the treatment of HR+/HER2– metastatic breast cancer. Mutational testing is paramount to guide the appropriate selection of therapies in both the frontline setting and for disease progression. From a managed care perspective, the rising cost of managing metastatic breast cancer requires careful consideration of resource utilization. Experts will lead a discussion on strategies for managed care professionals to improve access to oral treatments for HR+/HER2– metastatic breast cancer, appropriately apply genomic testing to ensure biomarker-directed therapy, and facilitate coverage policies that support patient access to care.
Learning Objectives
- Apply the guideline recommendations for mutational testing and associated treatment selection in HR+ metastatic breast cancer.
- Compare recent clinical trial data for triplet regimen with the historic standard of care in frontline treatment algorithms for HR+/HER2– metastatic breast cancer.
- Analyze the evolving role of oral targeted agents and selective estrogen receptor degraders in the management of HR+/HER2– metastatic breast cancer.
- Investigate the impact of recent clinical updates on formulary decisions, treatment pathways, and resource allocation for patients with HR+/HER2– metastatic breast cancer within operational and managed care frameworks.
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com - Wednesday, April 2, 2025 | 6:00 am - 8:00 am
-
Location: 370 DEF
Evaluating the Effectiveness and Value of Novel Nonhormonal Treatments in the Management of Menopause-Related Vasomotor Symptoms
Provider: Pharmacy Times Continuing Education
Supported by: Bayer US
Continuing education: Managed Care Pharmacist
Contact hours: 1.5
Program Description
Menopause is a life-changing transition for women and can often lead to challenges in sleep patterns, daily routines, and quality of life. Vasomotor symptoms (VMS), such as hot flashes and night sweats, are common, with estimates suggesting 60% to 85% of women experience them. This session will focus on the impact of VMS on health-related quality of life, with real-world data underscoring the burden of these symptoms and disparities in access to effective treatment. While hormone therapy remains a viable option for many women, its use is not without risks and is not recommended for all women, which underscores the importance of individualized treatment approaches. Expert faculty will discuss managed care considerations for evidence-based, targeted treatment of VMS, with a focus on the efficacy and safety profiles of novel nonhormonal therapies, such as neurokinin 3 receptor (NK3R) antagonists, that target the underlying mechanisms of VMS. The session will prepare managed care professionals with strategies for applying evidence to ensure access to the most appropriate and effective therapies, including eligibility/exclusion criteria, shared decision-making, and the value of nonhormonal therapies for VMS.
Learning Objectives
- Explain the health burden associated with vasomotor symptoms (VMS) in menopause and the risk/benefit profile of hormonal therapy.
- Examine the efficacy and safety data for novel nonhormonal therapies in the treatment of bothersome menopause symptoms, including VMS and sleep disturbances.
- Explore the health care resource utilization and economic burdens associated with VMS and the need for a personalized treatment approach to improve menopause-related quality of life.
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com - Wednesday, April 2, 2025 | 11:30 am - 1:30 pm
-
Location: 330
Precision Meets Value: Elevating Outcomes in Relapsed/Refractory Multiple Myeloma With CAR T-Cell and Bispecific Antibody Therapies
Provider: PRIME Education, LLC
Supported by: Janssen Scientific Affairs, LLC, Legend Biotech, BMS (Pending)
Continuing education: ACPE credit for managed care pharmacists, medical and pharmacy directors, and medication therapy management (MTM) nursing directors working in managed care organizations, pharmacy benefit organizations, and specialty pharmacies
Contact hours: 1.5Program Description
The 1.5-hour live symposium and live stream will be led by a panel of one nationally renowned expert in MM, a managed care pharmacist and moderated by a clinical pharmacist to facilitate panel discussions, conduct polling, and triage questions from the audience.
The symposium’s agenda will feature real-world insights from a new managed care pharmacist survey and expert discussion on the latest evidence for bispecific antibody and CAR T-cell therapies in R/R MM, with a focus on overcoming managed care challenges and improving patient outcomes. To maximize audience engagement, the presentation will integrate real-time polling and case-based discussions supplemented by pre-submitted attendee questions and a dedicated Q&A session.
Agenda
I. Shifting the Paradigm: The Role of CAR T-Cell and Bispecific Antibody Therapies in R/R MM
a. Key updates from clinical trials and their implications for earlier treatment with CAR T-cell therapy in R/R MM
b. Optimizing patient outcomes in R/R MM: Case-based discussions
II. Real-World Insights: Survey of Managed Care Pharmacists on the Challenges and Opportunities With CAR T-Cell Therapies and Bispecific T-Cell Engagers
III. Financial Toxicity and Healthcare Resource Management: Strategies for Managed Care Pharmacists
a. Cost considerations for bispecific and CAR T-cell therapies
b. Innovative reimbursement models, such as outcome-based pricing
c. Best practices for financial navigation, outpatient management of CRS, and remote patient monitoring
d. The role of managed care pharmacists in advocating for expanded networks of certified CAR T-cell centers
IV. Q&A Session
Learning Objectives
- Analyze the latest efficacy and safety data on chimeric antigen receptor (CAR) T-cell and bispecific antibody therapies to inform formulary decisions for relapsed/refractory multiple myeloma (R/R MM)
- Apply evidence-based strategies to optimize patient selection criteria for CAR T-cell therapies and bispecific antibodies in R/R MM management, based on patient- and disease-specific factors
- Assess the impact of early identification and management of adverse events (AEs) in patients receiving CAR T-cell therapies and bispecific antibodies to enhance safety and reduce costs
- Evaluate the cost-effectiveness and financial implications of utilizing CAR T-cell therapies and bispecific antibodies in managed care settings for R/R MM treatment
- Employ strategies to mitigate financial toxicity for R/R MM patients undergoing treatment with CAR T-cell therapies and bispecific antibodies
Program Manager
Stephanie Yang
PRIME Education
s.yang@primeinc.org - Wednesday, April 2, 2025 | 11:30 am - 1:30 pm
-
Location: 370 DEF
11:30 AM-12:00 PM CDT: Registration & Lunch
12:00-1:00 PM CDT: In-Person & Virtual Symposium
Taking a Step Forward in HCM Precision Medicine: Aligning Clinical and Managed Care Approaches With New Guidelines, Long-Term Evidence, and Real-World Experience
Provider: This CME/MOC/CPE/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.
Supported by: This activity is supported through an educational grant from Bristol Myers Squibb.
Continuing education: This activity has been designed to meet the educational needs of managed care, specialty, and health system pharmacists, medical directors, cardiologists, and other clinicians involved in the management of patients with HCM.
Contact hours: 1.0 CME/MOC/CPE/AAPA/IPCEProgram Description
Hypertrophic cardiomyopathy (HCM) is a cardiac condition affecting up to 1 in 200 individuals. For those who advance to severe symptomatic obstructive HCM (oHCM), surgical and pharmacological treatments are recommended to manage symptoms and reduce risks. However, most conventional treatments address symptoms only and do not directly target the underlying pathophysiology. In contrast, cardiac myosin inhibitors (CMIs) target the underlying pathophysiology of oHCM, alleviate symptoms, and improve functional outcomes. One CMI is currently approved for oHCM, with other agents and indications on the horizon. To realize the full potential of CMIs, this class must be integrated into treatment protocols—a challenge under many current pharmacy coverage policies. How should managed care professionals and healthcare providers respond?
This PeerView Clinical Consults satellite symposium during the 2025 Academy of Managed Care Pharmacy (AMCP) Annual Meeting will answer that question and more. This activity integrates key research insights with their practical application through patient scenarios. By the end of the symposium, learners will better grasp the challenges of the HCM treatment journey, as well as the long-term and real-world evidence critical to aligning therapeutic decision-making with managed care strategies. Learners will then be able to take this knowledge and understand how to integrate it into updated managed care frameworks and team-based care. Register now and step forward the future of precision medicine in HCM!
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify the clinical and financial burdens associated with HCM that contribute to suboptimal health and economic/resource utilization outcomes
- Explain the latest recommendations and evidence critical to aligning managed care strategies with therapeutic decision-making in oHCM
- Incorporate clinical features, pharmacoeconomic considerations, health equity, and patient-related factors into updated managed care frameworks and interprofessional strategies for the precision treatment of oHCM
Program Manager
Amanda Loeber
PVI, PeerView Institute for Medical Education
amanda.loeber@peerview.com - Wednesday, April 2, 2025 | 11:30 am - 1:30 pm
-
Location: 370 ABC
Optimizing the Uptake of Long-Acting Injectables in HIV Treatment and Prevention: Considerations for Managed Care
Provider: Pharmacy Times Continuing Education
Supported by: ViiV Healthcare
Continuing education: Managed Care Pharmacist
Contact hours: 1.5
Program Description
HIV is a chronic condition affecting over 1 million people in the United States, and many people living with HIV experience systemic barriers to care that limit treatment access and adherence. Long-acting injectables (LAIs) have extended the administration schedule for antiretroviral regimens, but challenges in the management of these therapies still remain. Pharmacists practicing in managed care can be central to identifying people with increased risk behaviors for HIV transmission, reviewing evidence-based recommendations for inclusion of LAIs within formularies and treatment protocols, and monitoring for treatment adherence and efficacy. Additionally, ensuring that people who are eligible for pre-exposure prophylaxis (PrEP) requires that managed care professionals and pharmacists implement projects designed to improve the uptake of PrEP LAIs. This session will review key aspects to improving access and adherence to LAIs, including programs emphasizing equitable implementation in HIV care and real-time decision-making with patients. Detailed information on the route of administration and dosing schedules for LAIs and how they can be effectively incorporated into HIV care plans will also be discussed.
Learning Objectives
- Identify patient populations who may benefit from HIV long-acting injectables (LAIs) based on clinical guidelines, risk factors, and patient preferences.
- Differentiate between the various HIV LAIs available, including their mechanisms of action, dosing regimens, and appropriate indications for use.
- Apply managed care strategies to optimize the uptake of HIV LAIs among eligible patients, including coverage policies, patient education, and provider engagement initiatives.
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com - Wednesday, April 2, 2025 | 11:30 am - 1:30 pm
-
Location: 340
Managed Care Approaches and Models for Equitable Access to Innovations in Major Depressive Disorder Treatment
Provider: Pharmacy Times Continuing Education
Supported by: Axsome Therapeutics, Inc.
Continuing education: Managed Care Pharmacist
Contact hours: 1.5
Program Description
Major depressive disorder (MDD) is a mental health issue that accounts for significant impact on patient quality of life, health care utilization, and economic costs. Treatment aims to overcome symptoms, minimize adverse drug reactions, and improve remission rates. Despite available treatments, many patients fail to achieve relief, and the recurrent nature of MDD contributes to 80% of patients experiencing at least 1 additional episode. The significant burden of MDD and challenges with treatment-resistant depression (TRD) is also complicated by patient challenges with adhering to long-term maintenance therapy. Expert faculty will discuss guideline recommendations for long-term versus episodic treatment, highlight innovative therapies targeting novel pathways, and review approaches for managed care professionals to improve MDD management by facilitating medication access, conducting reviews, and optimizing adherence. This session will provide valuable insights for managed care professionals on optimizing the management of MDD and TRD, including strategies for relapse prevention to enhance patient outcomes and improve cost-effectiveness.
Learning Objectives
- Examine the clinical and economic burden, as well as the unmet needs in the treatment approach to major depressive disorder (MDD) and treatment-resistant depression.
- Explore recent advancements in MDD treatments, evaluating the safety and efficacy of new agents while addressing barriers to treatment. adherence.
- Identify strategies for managed care pharmacists to improve patient outcomes in MDD by optimizing therapy selection, enhancing medication access, and supporting adherence, with a focus on personalized, patient-centered care.
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com - Wednesday, April 2, 2025 | 6:00 pm - 8:00 pm
-
Location: 370 ABC
Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management
Provider: Pharmacy Times Continuing Education (PTCE)
Supported by: Incyte Corporation
Continuing education: Managed Care Pharmacist, Oncology Pharmacist
Contact hours: 1.5
Program Description
The JAK/STAT pathway plays a major role in the pathogenesis of myelofibrosis. JAK inhibitors improve symptoms of myelofibrosis but may cause cytopenias and have modest effects on bone marrow fibrosis. Patients often develop clinical resistance over time, making switching to another JAK inhibitor therapy a promising treatment option. This session will provide an overview of myelofibrosis, outlining its significant clinical burden and how the use of newer agents in more personalized treatment approaches may address myelofibrosis progression and improve outcomes for patients with relapsed/refractory disease. Key managed care considerations, such as treatment selection, sequencing, and cost-effectiveness will be discussed. The discussion will encompass strategies for oncology and managed care professionals to optimize treatment plans, ensuring patients receive appropriate medications, with a focus on managing treatment-related toxicities, minimizing disease progression, and improving quality of life for patients with myelofibrosis.
Learning Objectives
- Differentiate between the approved JAK inhibitors based on clinical data and guideline recommendations for use in the treatment of myelofibrosis.
- Explore evidence-based second-line treatment plans for patients with myelofibrosis who have relapsed, are refractory, or have developed intolerance to previous JAK inhibitor therapy.
- Explore managed care strategies that facilitate appropriate treatment and supportive care for patients with myelofibrosis, aimed at improving resource utilization and patient outcomes.
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com - Wednesday, April 2, 2025 | 6:00 pm - 8:00 pm
-
Location: 370 DEF
Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care
Provider: Pharmacy Times Continuing Education (PTCE)
Supported by: Genentech, a member of the Roche Group
Continuing education: Managed Care Pharmacist
Contact hours: 1.5
Program Description
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are leading causes of vision impairment worldwide and significantly impact patients' quality of life. This session will explore the latest advancements in the management of nAMD and DME, focusing on how real-world data can guide evidence-based treatment selection. The discussion will balance established and emerging anti-vascular endothelial growth factor (VEGF) inhibitors with novel administration and dosing parameters with ongoing treatment limitations, adherence challenges, and long-term safety and efficacy data. By examining the integration of real-world data with clinical guidelines, this session will empower managed care professionals and pharmacists to align coverage policies with emerging evidence and enhance care delivery and access for patients with nAMD and DME.
Learning Objectives
- Examine the incidence, prevalence, and unmet needs of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), including economic impact and patient challenges.
- Analyze the efficacy, safety, and administration considerations of available and emerging therapies for nAMD and DME, emphasizing how these factors influence treatment selection and patient management.
- Apply managed care considerations that incorporate evidence-based guidelines and real-world evidence to improve treatment efficacy, balance cost-effectiveness, and enhance patient access to innovative therapies.
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com - Thursday, April 3, 2025 | 6:00 am - 8:00 am
-
Location: 370 ABC
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Provider: Pharmacy Times Continuing Education (PTCE)
Supported by: GSK
Continuing education: Managed Care Pharmacist, Oncology Pharmacist
Contact hours: 1.5
Program Description
Endometrial cancer is the most common gynecologic malignancy in the US. While the majority of cases are diagnosed early and can be treated with surgery alone, for advanced or recurrent disease, the survival rate drops to below 20%. Immunotherapy-based regimens, such as immune checkpoint inhibitors, have shown promising results in improving survival and quality of life. While immunotherapy has shown significant promise, not all patients benefit, so identifying patients who are most likely to respond remains a challenge. This session will highlight best practices for appropriate use of immunotherapies in advanced endometrial cancer, outlining the utility of biomarker testing and translation to treatment selection. By developing protocols that advance precision medicine, ensure evidence-based sequencing of these therapies, and tailor treatment in gynecologic cancers, managed care and oncology pharmacists can play a crucial role in improving outcomes for patients. Strategies that incorporate immunotherapies into treatment plans and reduce inequities in medication access will also be discussed.
Learning Objectives
- Analyze the molecular pathways and genetic factors implicated in endometrial cancer to identify appropriate treatment strategies based on a patient's individual tumor profile.
- Interpret the most recent clinical data and evolving treatment guidelines for current and emerging immune-based therapies in the management of endometrial cancer to identify effective and appropriate treatment options for patients.
- Determine best practices for managed care in integrating the latest clinical evidence on immune-based therapies for endometrial cancer to ensure equitable access, appropriate utilization, and optimal patient outcomes.
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com - Thursday, April 3, 2025 | 6:00 am - 8:00 am
-
Location: 370 DEF
Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative
Provider: Pharmacy Times Continuing Education
Supported by: Cytokinetics
Continuing education: Managed Care Pharmacist
Contact hours: 1.5
Program Description
Hypertrophic cardiomyopathy (HCM) is a complex heart condition that is often underdiagnosed, leading to inadequate treatment and causing significant health care burden. New treatments, such as cardiac myosin inhibitors, target the underlying causes of HCM and offer symptom relief to patients. Managed care providers must be familiar with these new therapies to facilitate access and improve clinical outcomes. This program will explore the inclusion of cardiac myosin inhibitors within updated guidelines for managing HCM, as well as the challenges and limitations of conventional therapeutic approaches. Beyond pharmacologic management strategies, managed care professionals will review and discuss data-driven models for reducing health-related complications and burdens associated with HCM.
Learning Objectives
- Examine the prevalence of hypertrophic cardiomyopathy (HCM) and the clinical and economic burden of disease.
- Identify the pathophysiological targets of current therapies used in the management of HCM.
- Analyze the current treatment guidelines for HCM and the recent clinical trial data for new and emerging agents.
- Investigate managed care strategies that support evidence-based treatment in HCM that consider patient-specific factors, clinical guidelines, cost-effectiveness, and health equity principles within a collaborative care model.
Program Manager
Alex Thomas
Pharmacy Times Continuing Education
althomas@pharmacytimes.com